LAV GLOBAL MANAGEMENT COMPANY LIMITED

Thesis

LAV GLOBAL MANAGEMENT COMPANY LIMITED is a global investment firm with a strong focus on the biomedical and venture capital sectors. Their core investment thesis revolves around identifying and backing companies with the potential to develop breakthrough products that treat diseases and improve human health, emphasizing quality science and a long-term vision. The firm's strategy concentrates on biopharmaceuticals, human therapeutics, medical devices, and diagnostics. Geographically, LAV has a primary focus on China, with an increasing interest in the U.S., particularly for companies that have a connection to the Chinese market. They describe their investment approach as stage-agnostic, having supported companies from seed stage all the way to publicly-traded entities. LAV's philosophy is to 'bet on people, products, and quality science,' positioning themselves as a supportive partner for entrepreneurs. They prioritize long-term value creation over speculative investments, seeking attractive financial returns that are aligned with ethical, science-based product development. While specific fund sizes vary across their entities, LAV Global Management Company Limited reports $1.4 billion in AUM, LAV Investment Adviser Limited reports $2 billion in AUM, and Lav Biosciences Fund III, L.P. had approximately $200.6 million in assets. The firm is generally classified as a Venture Capital firm. They employ over 50 professionals and leverage a large network of scientific advisors. LAV was founded in 2008, initially as a corporate venture subsidiary of Eli Lilly, and became an independent investment management company in 2011.

Related lists

• Seed-stage Healthcare investors
• Series A Healthcare investors
• Series B Healthcare investors